Dr. Colin Goddard is former CEO of BlinkBio, and was formerly CEO of OSI Pharmaceuticals, raising over $1.5 billion and overseeing the development, launch and commercialization of Tarceva through to OSI’s $4 billion acquisition by Astellas. Dr. Goddard also Chairs the board of Mission Therapeutics and board member of ADC company Endocyte (a Novartis company). He obtained his PhD in cancer chemotherapy in the UK and completed post-doctoral training at the NCI in Bethesda, MD.
